We are thrilled to share that Biocytogen will attend the 14th Annual Tumor Models Summit Boston from July 29th - 30th. The premier industry event will unite over 200 industry leaders to share best practices and align strategies on de-risking clinical translation and leveraging reproducible tumor models. Come visit our booth to learn more about how Biocytogen’s established portfolio of oncology and immuno-oncology in vivo models and luciferase-labeled tumor cell lines can help support your preclinical research.
What is the 14th Tumor Models Summit Boston?
The 14th Tumor Models Summit Boston will be spread across two tracks, Tumor Model Applications in Drug Discovery & Screening and Tumor Model Applications for Efficacy Evaluation & Biomarker Discovery. Topics include optimizing in vitro, in vivo, ex vivo, and in silico models, AI foundational models, biomarkers, and more. Don’t miss this chance to gain new insights and discover the next generation of technologies driving the future of tumor models.
Event Overview
Date: July 29th - 30th, 2026
Venue: Hotel Commonwealth, 500 Commonwealth Avenue Boston, MA 02215
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
